CRYOPORT, INC. (CYRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 221.04M USD | Liabilities, Current |
| Cash and equivalents | 269.27M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 36.45M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 21.51M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $221.04M | $269.27M | (m) | $36.45M | $21.51M | (m) |
| 2026-03-31 | (m) | $224.87M | $272.91M | (m) | $39.00M | $21.75M | (m) |
| 2025-12-31 | (m) | $219.02M | $250.49M | (m) | $33.36M | $23.19M | (m) |
| 2025-09-30 | (m) | $30.75M | $255.81M | (m) | $34.91M | $23.33M | (m) |
| 2025-06-30 | (m) | $30.15M | $243.42M | (m) | $33.41M | $23.04M | (m) |
| 2025-03-31 | (m) | $74.03M | $36.10M | (m) | $28.37M | $23.34M | (m) |
| 2024-12-31 | (m) | $64.56M | $45.29M | (m) | $45.78M | $22.47M | (m) |
| 2024-09-30 | (m) | $61.44M | $44.66M | (m) | $43.46M | $23.55M | (m) |
| 2024-06-30 | (m) | $59.88M | $46.46M | (m) | $40.16M | $23.61M | (m) |
| 2024-03-31 | (m) | $48.98M | $49.66M | (m) | $41.25M | $25.02M | (m) |
| 2023-12-31 | (m) | $45.61M | $46.35M | (m) | $42.07M | $26.21M | (m) |
| 2023-09-30 | (m) | $44.91M | $59.47M | (m) | $42.63M | $29.10M | (m) |
| 2023-06-30 | (m) | $40.25M | $67.31M | (m) | $43.08M | $28.82M | (m) |
| 2023-03-31 | (m) | $41.58M | $38.54M | (m) | $45.57M | $26.49M | (m) |
| 2022-12-31 | (m) | $40.85M | $36.59M | (m) | $43.86M | $27.68M | (m) |
| 2022-09-30 | (m) | $40.73M | $30.72M | (m) | $44.42M | $24.54M | (m) |
| 2022-06-30 | (m) | $44.05M | $37.03M | (m) | $43.90M | $23.07M | (m) |
| 2022-03-31 | (m) | $44.44M | $134.45M | (m) | $35.84M | $22.06M | (m) |
| 2021-12-31 | (m) | $42.65M | $139.10M | (m) | $39.41M | $16.50M | (m) |
| 2021-09-30 | (m) | $41.07M | $43.68M | (m) | $38.46M | $13.48M | (m) |
| 2021-06-30 | (m) | $38.15M | $60.36M | (m) | $38.10M | $11.66M | (m) |
| 2021-03-31 | (m) | $37.87M | $85.49M | (m) | $36.50M | $11.54M | (m) |
| 2020-12-31 | (m) | $35.02M | $36.87M | (m) | $31.38M | $10.54M | (m) |
| 2020-09-30 | (m) | $13.19M | $161.99M | (m) | $7.78M | $476.62K | (m) |
| 2020-06-30 | (m) | $9.44M | $44.33M | (m) | $7.04M | $538.38K | (m) |
| 2020-03-31 | (m) | $7.07M | $50.62M | (m) | $6.14M | $464.59K | (m) |
| 2019-12-31 | (m) | $5.46M | $47.23M | (m) | $7.10M | $473.96K | (m) |
| 2019-09-30 | (m) | $5.71M | $44.59M | (m) | $7.50M | $350.92K | (m) |
| 2019-06-30 | (m) | $5.73M | $80.64M | (m) | $6.10M | $306.44K | (m) |
| 2019-03-31 | (m) | $4.53M | $32.77M | (m) | $4.21M | $227.09K | (m) |
| 2018-12-31 | (m) | $3.06M | $37.33M | (m) | $3.54M | $220.51K | (m) |
| 2018-09-30 | (m) | $2.79M | $13.85M | (m) | $3.20M | $130.30K | (m) |
| 2018-06-30 | (m) | $3.13M | $20.01M | (m) | $3.62M | $97.29K | (m) |
| 2018-03-31 | (m) | $2.44M | $18.99M | (m) | $2.39M | $121.93K | (m) |
| 2017-12-31 | (m) | $2.19M | $15.04M | (m) | $1.63M | $114.80K | (m) |
| 2017-09-30 | (m) | $1.77M | $15.40M | (m) | $1.46M | $90.25K | (m) |
| 2017-06-30 | (m) | $1.97M | $12.85M | (m) | $1.25M | $72.62K | (m) |
| 2017-03-31 | (m) | $2.63M | $14.53M | (m) | $1.47M | $70.96K | (m) |
| 2016-12-31 | (m) | $2.23M | $4.52M | (m) | $1.20M | $89.50K | (m) |
| 2016-09-30 | (m) | $2.29M | $2.56M | (m) | $1.00M | $82.19K | (m) |
| 2016-06-30 | (m) | $2.61M | $4.53M | (m) | $1.02M | $83.54K | (m) |
| 2016-03-31 | (m) | $2.17M | $2.79M | (m) | $1.02M | $69.80K | (m) |
| 2015-12-31 | (m) | $2.47M | $5.25M | (m) | $616.78K | $52.88K | (m) |
| 2015-09-30 | (m) | $2.20M | $7.06M | (m) | $702.91K | $79.23K | (m) |
| 2015-06-30 | (m) | $1.97M | $2.39M | (m) | $757.44K | $104.80K | (m) |
| 2015-03-31 | (m) | $3.00M | $1.41M | (m) | $589.70K | $69.68K | (m) |
| 2014-12-31 | (m) | $2.98M | $773.92K | (m) | $407.46K | $66.96K | (m) |
| 2014-09-30 | (m) | $2.58M | $103.34K | (m) | $408.08K | $58.80K | (m) |
| 2014-06-30 | (m) | $2.38M | $170.50K | (m) | $492.87K | $38.60K | (m) |
| 2014-03-31 | (m) | $4.01M | $369.58K | (m) | $515.83K | $29.70K | (m) |
| 2013-12-31 | (m) | $1.77M | $219.97K | (m) | $635.69K | $30.01K | (m) |
| 2013-09-30 | (m) | $1.04M | $532.47K | (m) | $387.67K | $43.30K | (m) |
| 2013-06-30 | (m) | $3.38M | $227.53K | (m) | $357.70K | $52.86K | (m) |
| 2013-03-31 | (m) | $2.50M | $563.10K | (m) | $217.10K | $39.21K | (m) |
| 2012-12-31 | (m) | $952.18K | $585.11K | (m) | $201.14K | $55.46K | (m) |
| 2012-09-30 | (m) | $713.09K | $1.67M | (m) | $170.37K | $55.92K | (m) |
| 2012-06-30 | (m) | $596.02K | $2.97M | (m) | $144.77K | $47.51K | (m) |
| 2012-03-31 | (m) | $1.11M | $4.62M | (m) | $146.12K | $51.75K | (m) |
| 2011-12-31 | (m) | $2.22M | $2.80M | (m) | $83.71K | $47.13K | (m) |
| 2011-09-30 | (m) | $2.53M | $4.95M | (m) | $111.39K | $42.68K | (m) |
| 2011-06-30 | (m) | $3.18M | $7.06M | (m) | $75.94K | $44.96K | (m) |
| 2011-03-31 | (m) | $3.24M | $9.28M | (m) | $55.79K | $44.22K | (m) |
| 2010-12-31 | (m) | (m) | $2.71M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $3.75M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $2.10M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $3.63M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |